Cardiff Oncology
CRDF
68 hedge funds and large institutions have $12.1M invested in Cardiff Oncology in 2016 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 24 reducing their positions, and 7 closing their positions.
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
3% more funds holding
Funds holding: 66 → 68 (+2)
8% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 24
10.74% less ownership
Funds ownership: 29.45% → 18.71% (-11%)
83% less capital inflows, than outflows
Capital inflows: $3.12M | Capital outflows: $18.4M
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $182K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$895K |
| 2 |
BlackRock Fund Advisors
San Francisco,
California
|
+$391K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
+$261K |
| 4 |
Morgan Stanley
New York
|
+$245K |
| 5 |
EP
Elkhorn Partners
Omaha,
Nebraska
|
+$221K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bridger Management
New York
|
-$14.8M |
| 2 |
Morgens Waterfall Vintiadis & Co
New York
|
-$1.35M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$705K |
| 4 |
Goldman Sachs
New York
|
-$237K |
| 5 |
Weiss Multi-Strategy Advisers
New York
|
-$220K |
CRDF Hedge Fund Activity: Q4 2016 in Review
68 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q4 2016, worth a combined $12.1M — down 70% from $40.5M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CRDF positions and 7 closed out — a net gain of 3 holders — while 22 added to existing stakes and 24 trimmed.
The largest buyer was Millennium Management, adding an estimated $895K. The largest seller was Bridger Management, exiting entirely with an estimated $14.8M sold.
- 68 institutional investors held Cardiff Oncology (CRDF) as of Q4 2016, up from 66 in Q3 2016.
- Funds reported $12.1M of Cardiff Oncology stock for Q4 2016, down 70% quarter-over-quarter.
- 10 funds opened new Cardiff Oncology positions in Q4 2016 and 7 closed out, a net change of +3 holders.
- The largest Cardiff Oncology buyer in Q4 2016 was Millennium Management, an estimated $895K added.
- The largest Cardiff Oncology seller in Q4 2016 was Bridger Management, an estimated $14.8M sold.
Based on aggregated 13F filings for Q4 2016.